Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)

v3.21.2
Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)
12 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]
    Years ended March 31,  
    2021     2020  
Research and development expenses   $ 2,444,148     $ 1,759,725  
Selling, general and administrative expenses     11,987,284       3,355,964  
Total stock-based compensation   $ 14,431,432     $ 5,115,689  
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
    Number of
Shares
    Weighted
Average
Grant-Date
 Fair Value
 
Unvested at March 31, 2019     -     $ -  
Granted     2,000,000     $ 2.46  
Vested     (749,997 )   $ 2.46  
Unvested at March 31, 2020     1,250,003     $ 2.46  
Granted     2,371,428     $ 3.47  
Canceled     (1,310,003 )   $ 2.38  
Vested     (1,533,650 )   $ 2.67  
Unvested at March 31, 2021     777,778     $ 5.12  
Share-based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]
    Year ended March 31,
2021
 
Dividend yield     0%  
Expected price volatility     50%  
Risk free interest rate     0.16% - 0.94%  
Expected term     1-7 years  
Share-based Payment Arrangement, Option, Activity [Table Text Block]
    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual
Term
(Years)
    Aggregate Intrinsic Value  
Outstanding at March 31, 2019     1,937,833     $ 0.54       9.2     $ 3,720,395  
Outstanding at March 31, 2020     1,937,833     $ 0.54       8.2     $ 4,243,610  
Granted     8,949,107     $ 3.23       8.4          
Exercised     (25,000 )   $ 0.15       -          
Outstanding at March 31, 2021     10,861,940     $ 2.73       8.0     $ 17,523,650  
                                 
Exercisable at March 31, 2021     10,382,079     $ 2.64       8.0     $ 17,361,817  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
    Shares Underlying Warrants     Weighted Average Exercise Price     Weighted Average Remaining Contractual
Term
(Years)
    Aggregate Intrinsic Value  
Outstanding at March 31, 2020     1,281,852     $ 1.91       3.0     $ -  
Issued     3,727,765     $ 2.95       4.7          
Exercised     (169,760 )   $ 4.17       -          
Canceled     (956,775 )   $ 1.67       -          
Outstanding at March 31, 2021     3,883,083     $ 2.49       4.6     $ 7,763,341  
                                 
Exercisable at March 31, 2021     3,267,698     $ 1.93       4.1     $ 6,320,439  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
    Year ended    
    March 31,
2021
   
Expected price volatility     50.0 %  
Risk free interest rate     0.4% - 2.4 %  
Expected term     5 years